Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Researchers discover novel metabolic gatekeeper mechanism for leukemia

Researchers discover novel metabolic gatekeeper mechanism for leukemia

Gene panel is effective at identifying problematic genes in common leukemia

Gene panel is effective at identifying problematic genes in common leukemia

Physicians receive Pfizer Prize for research on leukemia, cardiac arrhythmias

Physicians receive Pfizer Prize for research on leukemia, cardiac arrhythmias

NUS researchers discover a mechanism controlling the replenishment of blood cells

NUS researchers discover a mechanism controlling the replenishment of blood cells

Substances in tick saliva activate immune response-suppressing proteins in cattle

Substances in tick saliva activate immune response-suppressing proteins in cattle

Innovative breakthrough promises to diagnose DNA rearrangement mutations

Innovative breakthrough promises to diagnose DNA rearrangement mutations

If I have cancer, dementia or MS, should i get the covid vaccine?

If I have cancer, dementia or MS, should i get the covid vaccine?

Two enzymes fuel transition from pre-cancer stem cells to leukemia stem cells

Two enzymes fuel transition from pre-cancer stem cells to leukemia stem cells

Study uses computational framework to identify tamoxifen resistance markers in ER+ breast cancer

Study uses computational framework to identify tamoxifen resistance markers in ER+ breast cancer

Anti-emetic drug offers a promising approach to treat chronic myeloid leukemia

Anti-emetic drug offers a promising approach to treat chronic myeloid leukemia

Prostate cancer: Drug-resistant, metastasis-causing cells can produce exponentially growing tumors

Prostate cancer: Drug-resistant, metastasis-causing cells can produce exponentially growing tumors

Drug intervention may prevent heart damage caused by chemotherapy

Drug intervention may prevent heart damage caused by chemotherapy

New maintenance treatment for AML shows strong benefit for patients

New maintenance treatment for AML shows strong benefit for patients

Infusion of convalescent blood plasma benefits patient with severe COVID-19

Infusion of convalescent blood plasma benefits patient with severe COVID-19

Modified version of CAR T-cell therapy shows promise in targeting neuroblastoma

Modified version of CAR T-cell therapy shows promise in targeting neuroblastoma

New study helps understand molecular profile of tumors in cancer patients

New study helps understand molecular profile of tumors in cancer patients

Investigational combo therapy shows promise in treating TP53 mutant MDS and AML patients

Investigational combo therapy shows promise in treating TP53 mutant MDS and AML patients

Eliminating key gene could revive exhausted immune cells to battle solid tumors

Eliminating key gene could revive exhausted immune cells to battle solid tumors

Researchers identify new drug combination that can treat acute myeloid leukemia

Researchers identify new drug combination that can treat acute myeloid leukemia

Study: NTRK fusions are far more frequently seen in pediatric tumors

Study: NTRK fusions are far more frequently seen in pediatric tumors

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.